15 Both technologies are based on the CRISPR-Cas system but utilize different CRISPR-associated proteins, Cas13 for SHERLOCK and Cas12a for DETECTR, to achieve their highly specific diagnostic ...
Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two ...
With the recent development of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, gene editing has become efficient, convenient and programmable, leading to promising ...
1Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE 68198-5900 USA 2Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical ...
The emergent field of CRISPR/Cas sensing technology is showing promise as a new paradigm in clinical diagnostics, although widespread clinical adoption remains limited. This perspective paper ...
Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR Therapeutics and Dragonfly Therapeutics, if confirmed by the ...
It is the most studied CRISPR gene editing technique, even if others exist like CRISPR-Cas12 or Cas13. The company was founded in 2017 with a focus on developing the technology of “base editing”.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback